Laurette L. Bukasa

Laurette L. Bukasa

Auto-generated profile, based on publicly available information

Laurette L. Bukasa

Abu Dhabi Health Data Services, Abu Dhabi, United Arab Emirates

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Health Technology Assessment
Verified
Journal Article
Open access
CRChristine Rake
Christine Rake
CGClare Gilham
Clare Gilham
LBLaurette Bukasa
Laurette Bukasa
RORichard Ostler
Richard Ostler
MNMichelle Newton
Michelle Newton
JPJulian Peto
Julian Peto
Background: Randomised controlled trials demonstrating improved longevity are needed to justify high-dose vitamin D supplementation for older populations. Objectives: To demonstrate the feasibility of a large trial (n ≈ 20,000) of high-dose vitamin D in people aged 65–84 years through general practitioner (GP) practices, and to cluster randomise participating practices between open-label and double-blind randomisation to compare effects on recruitment, compliance and contamination. Design: Twenty GP practices were randomised in matched pairs between open-label and double-blind allocation. Within each practice, patients were individually randomised to vitamin D or control (i.e. no treatment or placebo). Participants were invited to attend their GP practice to provide a blood sample and complete a lifestyle questionnaire at recruitment and again at 2 years. Randomisation by telephone followed receipt of a serum corrected calcium assay confirming eligibility (< 2.65 nmol/l). Treatment compliance was reported by quarterly follow-up forms sent and returned by e-mail or post (participant choice). GP visits and infections were abstracted from GP records. Hospital attendances, cancer diagnoses and deaths were ascertained by linkage to Hospital Episode Statistics and national registration through NHS Digital. Setting: GP practices in England. Participants: Recruitment opened in October 2013 and closed in January 2015. A total of 1615 registered patients aged 65–84 years were randomised: 407 to vitamin D and 421 to no treatment in open practices; 395 to vitamin D and 392 to placebo in blind practices. Interventions: There was a 24-month treatment period: 12 monthly doses (100,000 IU of vitamin D3 or placebo as 5 ml oily solution) were posted after randomisation and at 1 year (100,000 IU per month corresponds to 3300 IU per day). Reminders were sent monthly by e-mail, text message or post. Main outcome measures: Recruitment, compliance, contamination and change in circulating 25-hydroxyvitamin D [25(OH)D] from baseline to 2 years. Results: Participation rates (randomised/invited) were 15.0% in open practices and 13.4% in double-blind practices (p = 0.7). The proportion still taking study medication at 2 years was 91.2% in open practices and 89.2% in double-blind practices (p = 0.4). The proportion of control participants taking > 400 IU vitamin D per day at 2 years was 5.0% in open practices and 4.8% in double-blind practices. Mean serum 25(OH)D concentration was 51.5 nmol/l [95% confidence interval (CI) 50.2 to 52.8 nmol/l] with 82.6% of participants < 75 nmol/l at baseline. At 2 years, this increased to 109.6 nmol/l (95% CI 107.1 to 112.1 nmol/l) with 12.0% < 75 nmol/l in those allocated to vitamin D and was unaltered at 51.8 nmol/l (95% CI 49.8 to 53.8 nmol/l) in those allocated to no vitamin D (no treatment or placebo). Conclusions: A trial could recruit 20,000 participants aged 65–84 years through 200 GP practices over 2 years. Approximately 80% would be expected to adhere to allocated treatment (vitamin D or placebo) for 5 years. The trial could be conducted entirely by e-mail in participants aged < 80 years, but some participants aged 80–84 years would require postal follow-up. Recruitment and treatment compliance would be similar and contamination (self-administration of vitamin D) would be minimal, whether control participants are randomised openly to no treatment with no contact during the trial or randomised double-blind to placebo with monthly reminders. Trial registration: Current Controlled Trials ISRCTN46328341 and EudraCT database 2011-003699-34. Funding: This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 10. See the NIHR Journals Library website for further project information.

18 February 2022 in HIV Medicine
Verified
Journal Article
Open access
PDF file
VRVirginia Rasi
Virginia Rasi
HPHelen Peters
Helen Peters
RSRebecca Sconza
Rebecca Sconza
KFKate Francis
Kate Francis
LBLaurette Bukasa
Laurette Bukasa
MCMario Cortina‐Borja
Mario Cortina‐Borja
Introduction HIV treatment recommendations have evolved over time, reflecting both growing availability of new antiretrovirals and accumulating evidence on their safe and effective use. We analysed patterns of antiretroviral use among diagnosed pregnant women living with HIV delivering in the UK and Ireland between 2008 and 2018 using national surveillance data. Methods All singleton pregnancies with known outcomes and known timing of antiretroviral initiation reported to the National Surveillance of HIV in Pregnancy and Childhood were included. Every individual instance of specific antiretroviral use was the unit of analysis in generating a snapshot of antiretroviral use overall and over calendar time. The final analysis was restricted to the 14 most frequently prescribed antiretrovirals. Results There were 12 099 singleton pregnancies reported during 2008–2018 and a total of 38 214 individual uses of the 14 most commonly prescribed antiretrovirals, the majority of which were started before conception (70.9%). In 2008, 37.7% (482/1279) of pregnancies were conceived under treatment, reaching 80.9% (509/629) by 2018. Patterns of antiretroviral use have changed over time, particularly for third agents. Between 2008 and 2018 the most frequently used protease inhibitor shifted from lopinavir to darunavir, whereas use of integrase inhibitors increased steadily over time. Conclusions These national surveillance data enable investigation of the ‘real-world’ use of antiretrovirals in pregnancy on a population level. Findings demonstrate mixed responsiveness of antiretroviral prescription to changes in pregnancy guideline recommendations and may also reflect changes in commissioning and in the characteristics of pregnant women living with HIV.

1 October 2023 in Journal of the International AIDS Society
Verified
Journal Article
Open access
LBLaurette L. Bukasa
Laurette L. Bukasa
ANAngelina Namiba
Angelina Namiba
MBMatilda Brown
Matilda Brown
ENEstelle Ndu'NGu
Estelle Ndu'NGu
MNMercy Nangwale
Mercy Nangwale
STShema Tariq
Shema Tariq
Introduction: There is growing interest in health, developmental and survival outcomes of children who are born HIV‐free to women living with HIV (children born HIV‐free). To date, the research agenda has been largely determined by researchers, funders and policy makers, with limited involvement of parents, who are key stakeholders. Researchers at UCL Great Ormond Street Institute of Child Health in partnership with community‐based organisation 4M Network of Mentor Mothers conducted two workshops with parents in March 2022 to establish research priorities for children born HIV‐free, and key considerations for methodological approaches both to research and engagement with the affected communities.Discussion: When exploring research on children born HIV‐free, we consider the following: what aspects of current research are aligned with women and parents’ priorities, what is missing and what approaches would be preferred. A holistic approach to research on children born HIV‐free should be prioritised, focussing on a breadth of outcomes and how they intersect. Secondary use of existing data sources should be maximised to facilitate this, with a view of monitoring the long‐term effects of fetal antiretroviral drug exposure alongside other key health and developmental outcomes. Involving and engaging with parents, and children where possible, must be at the heart of research design to maximise relevance and impact of findings for the affected communities. Potential barriers to engaging with individuals who were children born HIV‐free include parental disclosure and individuals not identifying as a child born HIV‐free to a mother living with HIV. Stigma‐free language must be incorporated into the vocabulary of researchers and other stakeholders, avoiding reference to exposure; we propose the term “children born HIV‐free.”Conclusions: Mothers and parents living with HIV should be involved in research about their children born HIV‐free and are key in identifying research priorities so that findings may translate into an impact on their children's health and wellbeing. Meaningful involvement of women living with HIV through trusted community partners is an effective mechanism by which to elicit views on research about their children.

3 April 2023 in Journal of the International AIDS Society
Verified
Journal Article
Open access
LBLaurette L. Bukasa
Laurette L. Bukasa
MCMario Cortina‐Borja
Mario Cortina‐Borja
HPHelen Peters
Helen Peters
GTGraham P. Taylor
Graham P. Taylor
CTClaire Thorne
Claire Thorne
Introduction: The prevalence of gestational diabetes (GD) is increasing globally. While universal risk factors for GD are reasonably well understood, questions remain regarding risks for women living with HIV (WLWH). We aimed to describe GD prevalence, evaluate associated maternal risk factors and assess specific birth outcomes in WLWH in the UK and Ireland.Methods: We analysed all pregnancies (≥24 weeks’ gestation) in women diagnosed with HIV before delivery, reported to the UK‐based Integrated Screening Outcomes Surveillance Service between 2010 and 2020. Every report of GD was considered as a case. A multivariable logistic regression model, adjusted for women with more than one pregnancy fitted with generalized estimating equations (GEE) assessed the effect of independent risk factors.Results: There were 10,553 pregnancies in 7916 women, of which 460 (4.72%) pregnancies had reported GD. Overall, the median maternal age was 33 years (Q1:29–Q3:37), and 73% of pregnancies were in Black African women. WLWH with GD (WLWH‐GD) were older (61% vs. 41% aged ≥35 years, p < 0.001) and more likely to be on treatment at conception (74% vs. 64%, p < 0.001) than women without GD. WLWH‐GD were more likely to have a stillbirth (odds ratio [OR]: 5.38, 95% CI: 2.14–13.5), preterm delivery (OR: 2.54, 95% CI: 1.95–3.32) and fetal macrosomia (OR: 1.14, 95% CI: 1.04–1.24). Independent risk factors for GD included estimated year of delivery (GEE‐adjusted odds ratio [GEE‐aOR]: 1.14, 95% CI: 1.10–1.18), advanced maternal age (≥35 years) (GEE‐aOR: 2.87, 95% CI: 1.54–5.34), Asian (GEE‐aOR: 2.63, 95% CI: 1.40–4.63) and Black African (GEE‐aOR: 1.55, 95% CI: 1.13–2.12) ethnicity. Timing and type of antiretroviral therapy showed no evidence of a relationship with GD in multivariable analyses; however, women with a CD4 count ≤350 cells/μl were 27% less likely to have GD than women with CD4 counts >350 cells/μl (GEE‐aOR: 0.73, 95% CI: 0.50–0.96).Conclusions: GD prevalence increased over time among WLWH but was not significantly different from the general population. Maternal age, ethnicity and CD4 count were risk factors based on available data. Stillbirth and preterm delivery were more common in WLWH‐GD than other WLWH over the study period. Further studies are required to build upon these results.

10 June 2025 in HIV Medicine
Verified
Journal Article
Open access
HOH. Okhai
H. Okhai
ABA. Baskaran
A. Baskaran
LBL. Bukasa
L. Bukasa
HPH. Peters
H. Peters
CTC. Thorne
C. Thorne
CSCaroline Anne Sabin
Caroline Anne Sabin
Objective: In this study, we explore changes in the demographic and clinical characteristics of pregnant people living with HIV, and their post‐partum HIV outcomes between 2000 and 2018. Methods: We described pregnancies resulting in a live birth from the linked UK CHIC/ISOSS dataset in three calendar periods (2000–2006; 2007–2012; 2013–2018). Thereafter, we explored median CD4 count change and viral rebound from delivery to 12 months post‐partum. Results: In total, 4341 pregnancies were included. Maternal age increased from 31 (IQR: 28–35) years in 2000–2006 to 34 (IQR: 30–37) years in 2013–2018. Those conceiving in the most recent period had been diagnosed with HIV for longer (2000–2006: 3.0 years to 2013–2018: 7.5 years), had a higher median CD4 count (431–583 cells/mm 3 ), and median nadir CD4 count (219–260 cells/mm 3 ); they were also more likely to have initiated ART prior to estimated conception (70.1%–92.3%), and have a suppressed conception viral loads (VL) (56.6%–82.0%). There was no difference in median CD4 count change over the three calendar periods (2000–2006: +60 [IQR: −44, +179]; 2007–2012: +51 [−45, +172]; 2013–2018: +28 [−100, +175] cells/mm 3 ; p = 0.12). The cumulative proportion of people with viral rebound at 12 months post‐delivery was reduced in 2013–2018 (8.2%) when compared with previous periods (2000–2006: 28.1%; 2007–2012: 19.5%). Conclusion: Clinical management of pregnant people has changed over time, resulting in positive trends in this study both within pregnancy and post‐partum. Further work needs to understand what barriers remain for those who do not achieve optimal management of HIV in the post‐partum period.

1 June 2026 in Intestinal Research
Verified
Journal Article
Open access
PDF file
TSThaer Khaleel Swaid
Thaer Khaleel Swaid
LHLayth Raafat Hamzeh
Layth Raafat Hamzeh
LBLaurette L. Bukasa
Laurette L. Bukasa
TJTine Jess
Tine Jess
MQMohammed Nabil Quraishi
Mohammed Nabil Quraishi
Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunity–findings from the UAE Epi-IBD study